Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy

Sofia Koustoulidou, Mark W H Hoorens, Simone U Dalm, Shweta Mahajan, Reno Debets, Yann Seimbille, Marion de Jong, Sofia Koustoulidou, Mark W H Hoorens, Simone U Dalm, Shweta Mahajan, Reno Debets, Yann Seimbille, Marion de Jong

Abstract

Cancer Associated Fibroblasts (CAFs) form a major component of the tumour microenvironment, they have a complex origin and execute diverse functions in tumour development and progression. As such, CAFs constitute an attractive target for novel therapeutic interventions that will aid both diagnosis and treatment of various cancers. There are, however, a few limitations in reaching successful translation of CAF targeted interventions from bench to bedside. Several approaches targeting CAFs have been investigated so far and a few CAF-targeting tracers have successfully been developed and applied. This includes tracers targeting Fibroblast Activation Protein (FAP) on CAFs. A number of FAP-targeting tracers have shown great promise in the clinic. In this review, we summarize our current knowledge of the functional heterogeneity and biology of CAFs in cancer. Moreover, we highlight the latest developments towards theranostic applications that will help tumour characterization, radioligand therapy and staging in cancers with a distinct CAF population.

Keywords: CAFs; FAP; radionuclide therapy; theranostics.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Potential cellular sources for cancer associated fibroblasts (CAFs). Several cellular types might yield CAFs in the TME. This includes normal fibroblasts through activation, recruitment and differentiation of bone marrow-derived mesenchymal stem cells (MSCs); epithelial cells through epithelial-to-mesenchymal transition (EMT) and endothelial cells through endothelial-to-mesenchymal transition (EndMT). Another source could be adipocytes through upregulated expression of mesenchymal bone marrow lineage-committed markers.
Figure 2
Figure 2
Diverse functions of CAFs: promotion of tumour growth, angiogenesis, cell invasion and metastasis to surrounding tissues, regulation of innate and adaptive immune responses. In addition to tumour-protective roles, CAFs occasionally have anti-tumorigenic functions. VEGF: Vascular Endothelial Growth Factor, FAP: Fibroblast Activation Protein, MMPs: Matrix Metalloproteinases, PDGF: Platelet-Derived Growth Factor, IL-6: Interleukin 6, CD146: Cluster of Differentiation 146, HGF: Hepatocyte Growth Factor, FSP1: Fibroblast-specific Protein 1.
Figure 3
Figure 3
ECM fiber structures from normal pancreatic stellate cells and pancreatic adenocarcinoma associated fibroblasts stained for anti-fibronectin (green). ECMs organized in parallel patterns were observed in pancreatic adenocarcinoma fibroblasts that are similar to those formed by FAP-positive matrices. In contrast, ECM structures of normal pancreatic stellate cells resemble more FAP-negative matrices. Nuclei were stained with DAPI (blue). Reproduced with permission from [39].
Figure 4
Figure 4
Overview of potential CAF interventions. (A) Use of anti-FAP mAbs or T-cells gene-engineered to express a FAP recognizing mAb (e.g., CAR-T cells) target FAP+ CAFs and result in their immune cell-mediated destruction and removal. (B) Enzymatic breakdown of HA may lead to remodelling of ECM and better tumour accessibility for drugs and/or immune cells. (C) Block CAF activity through IL-6. (D) Transform CAFs into a more quiescent state via Vitamin D. (E) Tackle the metabolic need of tumour cells and their dependence on CAF metabolism. FAP: fibroblast activated protein, CAR: chimeric antigen receptor, HA: hyaluronic acid, IL-6 interleukin-6.

References

    1. Cancer [Internet] [(accessed on 19 November 2020)]; Available online: .
    1. Valkenburg K.C., de Groot A.E., Pienta K.J. Targeting the tumour stroma to improve cancer therapy. Nat. Rev. Clin. Oncol. 2018;15:366–381. doi: 10.1038/s41571-018-0007-1.
    1. Yuan Y., Jiang Y.C., Sun C.K., Chen Q.M. Role of the tumor microenvironment in tumor progression and the clinical applications (Review) Oncol. Rep. 2016;35:2499–2515. doi: 10.3892/or.2016.4660.
    1. Balkwill F.R., Capasso M., Hagemann T. The tumor microenvironment at a glance. J. Cell Sci. 2012;125:5591–5596. doi: 10.1242/jcs.116392.
    1. Liu L., Liu L., Yao H.H., Zhu Z.Q., Ning Z.L., Huang Q. Stromal myofibroblasts are associated with poor prognosis in solid cancers: A meta-analysis of published studies. PLoS ONE. 2016;11:e0159947. doi: 10.1371/journal.pone.0159947.
    1. Trabelsi M., Farah F., Zouari B., Jaafoura M.H., Kharrat M. An immunoscore system based on cd3+ and cd8+ infiltrating lymphocytes densities to predict the outcome of patients with colorectal adenocarcinoma. Onco. Targets. Ther. 2019;12:8663–8673. doi: 10.2147/OTT.S211048.
    1. Liu T., Zhou L., Li D., Andl T., Zhang Y. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front. Cell Dev. Biol. 2019;7:1–14. doi: 10.3389/fcell.2019.00060.
    1. Öhlund D., Handly-Santana A., Biffi G., Elyada E., Almeida A.S., Ponz-Sarvise M., Corbo V., Oni T.E., Hearn S.A., Lee E.J., et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 2017;214:579–596. doi: 10.1084/jem.20162024.
    1. Kalluri R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 2016;6:582–598. doi: 10.1038/nrc.2016.73.
    1. Flier J.S., Underhill L.H., Dvorak H.F. Tumors: Wounds That Do Not Heal. N. Engl. J. Med. 1986;315:1650–1659. doi: 10.1056/NEJM198612253152606.
    1. Liu T., Han C., Wang S., Fang P., Ma Z., Xu L., Yin R. Cancer-associated fibroblasts: An emerging target of anti-cancer immunotherapy. J. Hematol. Oncol. 2019;12:1–15. doi: 10.1186/s13045-019-0770-1.
    1. Sahai E., Astsaturov I., Cukierman E., DeNardo D.G., Egeblad M., Evans R.M., Fearon D., Greten F.R., Hingorani S.R., Hunter T., et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer. 2020;20:174–186. doi: 10.1038/s41568-019-0238-1.
    1. Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., Onder T.T., Wang Z.C., Richardson A.L., Weinberg R.A., et al. Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA. 2010;107:20009–20014. doi: 10.1073/pnas.1013805107.
    1. Löhr M., Schmidt C., Ringel J., Kluth M., Müller P., Nizze H., Jesnowski R. Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 2001;61:550–555.
    1. Bu L., Baba H., Yoshida N., Miyake K., Yasuda T., Uchihara T., Tan P., Ishimoto T. Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene. 2019;38:4887–4901. doi: 10.1038/s41388-019-0765-y.
    1. Mishra P.J., Mishra P.J., Humeniuk R., Medina D.J., Alexe G., Mesirov J.P., Ganesan S., Glod J.W., Banerjee D. Carcinoma-associated fibroblast—Like differentiation of human MSC. Cancer. 2009;68:4331–4339. doi: 10.1158/0008-5472.CAN-08-0943.Carcinoma.
    1. Weber C.E., Kothari A.N., Wai P.Y., Li N.Y., Driver J., Zapf M.A.C., Franzen C.A., Gupta G.N., Osipo C., Zlobin A., et al. Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene. 2015;34:4821–4833. doi: 10.1038/onc.2014.410.
    1. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., Chandraker A., Yuan X., Pu W.T., Roberts A.B., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007;13:952–961. doi: 10.1038/nm1613.
    1. Tomiyama K., Murase N., Stolz D.B., Toyokawa H., O’Donnell D.R., Smith D.M., Dudas J.R., Rubin J.P., Marra K.G. Characterization of transplanted GFP+ bone marrow cells into adipose tissue. Stem Cells. 2008;26:330–338. doi: 10.1634/stemcells.2007-0567.
    1. Barth P.J., Ebrahimsade S., Ramaswamy A., Moll R. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions. Virchows Arch. 2002;440:298–303. doi: 10.1007/s004280100530.
    1. LeBleu V.S., Kalluri R. A peek into cancer-associated fibroblasts: Origins, functions and translational impact. DMM Dis. Model. Mech. 2018;11:1–9. doi: 10.1242/dmm.029447.
    1. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59:5002–5011.
    1. Hanahan D., Weinberg R.a. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013.
    1. Bhowmick N.A., Neilson E.G., Moses H.L. 6 Moses. [(accessed on 25 February 2021)];2004 :432. Available online: .
    1. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. PNAS. 2004;101:4966–4971. doi: 10.1073/pnas.0401064101.
    1. Grum-Schwensen B., Klingelhofer J., Berg C.H., El-Naaman C., Grigorian M., Lukanidin E., Ambartsumian N. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 2005;65:3772–3780. doi: 10.1158/0008-5472.CAN-04-4510.
    1. Li G., Satyamoorthy K., Meier F., Berking C., Bogenrieder T., Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: When seeds meet soil. Oncogene. 2003;22:3162–3171. doi: 10.1038/sj.onc.1206455.
    1. Avagliano A., Granato G., Ruocco M.R., Romano V., Belviso I., Carfora A., Montagnani S., Arcucci A. Metabolic Reprogramming of Cancer Associated Fibroblasts: The Slavery of Stromal Fibroblasts. Biomed Res. Int. 2018;2018 doi: 10.1155/2018/6075403.
    1. Powell D.W. Myofibroblasts: Paracrine cells important in health and disease. Trans. Am. Clin. Climatol. Assoc. 2000;111:271–293. doi: 10.1152/ajpcell.1999.277.1.C1.
    1. Yang N., Xiao W., Song X., Wang W., Dong X. Recent Advances in Tumor Microenvironment Hydrogen Peroxide-Responsive Materials for Cancer Photodynamic Therapy. Nano-Micro Lett. 2020;12:1–27. doi: 10.1007/s40820-019-0347-0.
    1. Rhim A.D., Oberstein P.E., Thomas D.H., Mirek E.T., Palermo F., Sastra S.A., Dekleva E.N., Saunders T., Becerra C.P., Tattersall I.W., et al. Stromal elements act to retrain rather than support pdac. Cancer Cell. 2014;25:735–747. doi: 10.1016/j.ccr.2014.04.021.
    1. Brechbuhl H.M., Finlay-Schultz J., Yamamoto T.M., Gillen A.E., Cittelly D.M., Tan A.C., Sams S.B., Pillai M.M., Elias A.D., Robinson W.A., et al. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin. Cancer Res. 2017;23:1710–1721. doi: 10.1158/1078-0432.CCR-15-2851.
    1. Lukashev M.E., Werb Z. ECM signalling: Orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 1998;8:437–441. doi: 10.1016/S0962-8924(98)01362-2.
    1. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N., Selig M., Nielsen G., Taksir T., Jain R.K., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94:715–725. doi: 10.1016/S0092-8674(00)81731-6.
    1. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007;9:1392–1400. doi: 10.1038/ncb1658.
    1. Lu P., Takai K., Weaver V.M., Werb Z. Extracellular Matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 2011;3:1–24. doi: 10.1101/cshperspect.a005058.
    1. Li J., Jia Z., Kong J., Zhang F., Fang S., Li X., Li W., Yang X., Luo Y., Lin B., et al. Carcinoma-associated fibroblasts lead the invasion of salivary gland adenoid cystic carcinoma cells by creating an invasive track. PLoS ONE. 2016;11:1–15. doi: 10.1371/journal.pone.0150247.
    1. Liu R., Li H., Liu L., Yu J., Ren X. Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol. Ther. 2012;13:123–129. doi: 10.4161/cbt.13.3.18696.
    1. Lee H.O., Mullins S.R., Franco-Barraza J., Valianou M., Cukierman E., Cheng J.D. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer. 2011;11:245. doi: 10.1186/1471-2407-11-245.
    1. Wang X.M., Yu D.M.T., McCaughan G.W., Gorrell M.D. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 2005;42:935–945. doi: 10.1002/hep.20853.
    1. Henry L.R., Lee H.O., Lee J.S., Klein-Szanto A., Watts P., Ross E.A., Chen W.T., Cheng J.D. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 2007;13:1736–1741. doi: 10.1158/1078-0432.CCR-06-1746.
    1. Cohen S.J., Alpaugh R.K., Palazzo I., Meropol N.J., Rogatko A., Xu Z., Hoffman J.P., Weiner L.M., Cheng J.D. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37:154–158. doi: 10.1097/MPA.0b013e31816618ce.
    1. Ju M.J., Qiu S.J., Fan J., Xiao Y.S., Gao Q., Zhou J., Li Y.W., Tang Z.Y. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am. J. Clin. Pathol. 2009;131:498–510. doi: 10.1309/AJCP86PPBNGOHNNL.
    1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002;29:15–18. doi: 10.1053/sonc.2002.37263.
    1. Hlatky L., Tsionou C., Hahnfeldt P., Coleman C.N. Mammary Fibroblasts May Influence Breast Tumor Angiogenesis Via Hypoxia-Induced Vascular Endothelial Growth Factor Up-Regulation And Protein Expression. Cancer Res. 1994;54:6083–6086.
    1. Shiga K., Hara M., Nagasaki T., Sato T., Takahashi H., Takeyama H. Cancer-associated fibroblasts: Their characteristics and their roles in tumor growth. Cancers. 2015;7:2443–2458. doi: 10.3390/cancers7040902.
    1. Gomes F.G., Nedel F., Alves A.M., Nör J.E., Tarquinio S.B.C. Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci. 2014;92:101–107. doi: 10.1016/j.lfs.2012.10.008.
    1. Grivennikov S.I., Greten F.R., Karin M., Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell. 2011;140:883–899. doi: 10.1016/j.cell.2010.01.025.
    1. Nagasaki T., Hara M., Shiga K., Takeyama H. Relationship between inflammation and cancer progression: Recent advances in interleukin-6 signaling and its blockage in cancer therapy. Recept. Clin. Investig. 2014:1–7. doi: 10.14800/rci.202.
    1. Wu X., Tao P., Zhou Q., Li J., Yu Z., Wang X., Li J., Li C., Yan M., Zhu Z., et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 2017;8:20741–20750. doi: 10.18632/oncotarget.15119.
    1. Harper J., Sainson R.C.A. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin. Cancer Biol. 2014;25:69–77. doi: 10.1016/j.semcancer.2013.12.005.
    1. An Y., Liu F., Chen Y., Yang Q. Crosstalk between cancer-associated fibroblasts and immune cells in cancer. J. Cell. Mol. Med. 2020;24:13–24. doi: 10.1111/jcmm.14745.
    1. Herrera M., Herrera A., Domínguez G., Silva J., García V., García J.M., Gómez I., Soldevilla B., Muñoz C., Provencio M., et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013;104:437–444. doi: 10.1111/cas.12096.
    1. De Boeck A., Hendrix A., Maynard D., Van Bockstal M., Daniëls A., Pauwels P., Gespach C., Bracke M., De Wever O. Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics. 2013;13:379–388. doi: 10.1002/pmic.201200179.
    1. Ma Y., Hwang R.F., Logsdon C.D., Ullrich S.E. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Bone. 2011;23:1–7. doi: 10.1158/0008-5472.CAN-12-4479.
    1. Gonzalez H., Hagerling C., Werb Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. 2018;32:1267–1284. doi: 10.1101/gad.314617.118.
    1. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE. 2009;4 doi: 10.1371/journal.pone.0007965.
    1. Pena C., Cespedes M.V., Lindh M.B., Kiflemariam S., Mezheyeuski A., Edqvist P.H., Hagglof C., Birgisson H., Bojmar L., Jirstrom K., et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res. 2013;73:1287–1297. doi: 10.1158/0008-5472.CAN-12-1875.
    1. Wang Y., Huang L., Abdelrahim M., Cai Q., Truong A., Bick R., Poindexter B., Sheikh-Hamad D. Stanniocalcin-1 suppresses superoxide generation in macrophages through induction of mitochondrial UCP2. J. Leukoc. Biol. 2009 doi: 10.1189/jlb.0708454.
    1. Chakraborty A., Brooks H., Zhang P., Smith W., McReynolds M.R., Hoying J.B., Bick R., Truong L., Poindexter B., Lan H., et al. Stanniocalcin-1 regulates endothelial gene expression and modulates transendothelial migration of leukocytes. Am. J. Physiol. Ren. Physiol. 2007;292:895–904. doi: 10.1152/ajprenal.00219.2006.
    1. Barnas J.L., Simpson-Abelson M.R., Yokota S.J., Kelleher R.J., Bankert R.B. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron. 2010;3:29–47. doi: 10.1007/s12307-010-0044-5.
    1. Cohen N., Shani O., Raz Y., Sharon Y., Hoffman D., Abramovitz L., Erez N. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene. 2017;36:4457–4468. doi: 10.1038/onc.2017.65.
    1. Ruhland M.K., Loza A.J., Capietto A.H., Luo X., Knolhoff B.L., Flanagan K.C., Belt B.A., Alspach E., Leahy K., Luo J., et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun. 2016;7 doi: 10.1038/ncomms11762.
    1. Hosein A.N., Wu M., Arcand S.L., Lavallée S., Hébert J., Tonin P.N., Basik M. Breast carcinoma-associated fibroblasts rarely contain p53 mutations or chromosomal aberrations. Cancer Res. 2010;70:5770–5777. doi: 10.1158/0008-5472.CAN-10-0673.
    1. Corver W.E., Haar N.T., Fleuren G.J., Oosting J. Cervical carcinoma-associated fibroblasts are DNA diploid and do not show evidence for somatic genetic alterations. Cell. Oncol. 2011;34:553–563. doi: 10.1007/s13402-011-0061-5.
    1. Kang N., Shah V.H., Urrutia R. Membrane-to-Nucleus Signals and Epigenetic Mechanisms for Myofibroblastic Activation and Desmoplastic Stroma: Potential Therapeutic Targets for Liver Metastasis? Physiol. Behav. 2015;13:604–612. doi: 10.1158/1541-7786.MCR-14-0542.
    1. Banerjee J., Mishra R., Li X., Ii R.S.J., Sharma A., Bhowmick N.A. A reciprocal role of prostate cancer on stromal DNA damage. Oncogene. 2013;33:4924–4931. doi: 10.1038/onc.2013.431.
    1. Albrengues J., Bertero T., Grasset E., Bonan S., Maiel M., Bourget I., Philippe C., Herraiz Serrano C., Benamar S., Croce O., et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat. Commun. 2015;6 doi: 10.1038/ncomms10204.
    1. Mitra A.K., Zillhardt M., Hua Y., Tiwari P., Murmann A.E., Peter M.E., Lengyel E. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012;2:1100–1108. doi: 10.1158/-12-0206.
    1. Zhao L., Sun Y., Hou Y., Peng Q., Wang L., Luo H., Tang X., Zeng Z., Liu M. MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer. Int. J. Biochem. Cell Biol. 2012;44:2051–2059. doi: 10.1016/j.biocel.2012.08.005.
    1. Pereira B.A., Vennin C., Papanicolaou M., Chambers C.R., Herrmann D., Morton J.P., Cox T.R., Timpson P. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. Trends Cancer. 2019;5:724–741. doi: 10.1016/j.trecan.2019.09.010.
    1. Lindner T., Loktev A., Giesel F., Kratochwil C., Altmann A., Haberkorn U. Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm. Chem. 2019;4:1–15. doi: 10.1186/s41181-019-0069-0.
    1. Ostermann E., Garin-Chesa P., Heider K.H., Kalat M., Lamche H., Puri C., Kerjaschki D., Rettig W.J., Adolf G.R. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 2008;14:4584–4592. doi: 10.1158/1078-0432.CCR-07-5211.
    1. Lo A., Wang L.S., Scholler J., Monslow J., Avery D., Newick K., Brien S.O., Evans R.A., Bajor D.J., Durham A.C., et al. Tumor-promoting desmoplasia is disrupted by depleting FAP- expressing stromal cells. Cancer Res. 2016;75:2800–2810. doi: 10.1158/0008-5472.CAN-14-3041.
    1. Lee J., Fassnacht M., Nair S., Boczkowski D., Gilboa E. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 2005;65:11156–11163. doi: 10.1158/0008-5472.CAN-05-2805.
    1. Gunderson A.J., Yamazaki T., McCarty K., Phillips M., Alice A., Bambina S., Zebertavage L., Friedman D., Cottam B., Newell P., et al. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. PLoS ONE. 2019;14:e0211117. doi: 10.1371/journal.pone.0211117.
    1. Scott A.M., Wiseman G., Welt S., Adjei A., Lee F.-T., Hopkins W., Divgi C.R., Hanson L.H., Mitchell P., Gansen D.N., et al. A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-Positive Cancer 1. Clin. Cancer Res. 2003;9:1639–1647.
    1. Roberts E.W., Deonarine A., Jones J.O., Denton A.E., Feig C., Lyons S.K., Espeli M., Kraman M., McKenna B., Wells R.J.B., et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 2013;210:1137–1151. doi: 10.1084/jem.20122344.
    1. Feig C., Jones J.O., Kraman M., Wells R.J.B., Deonarine A., Chan D.S., Connell C.M., Roberts E.W., Zhao Q., Caballero O.L., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA. 2013;110:20212–20217. doi: 10.1073/pnas.1320318110.
    1. Pargellis C.A., Campbell S.J., Pav S., Graham E.T., Pitner T.P. Inhibition of dipeptidyl peptidase IV (CD26) by peptide boronic acid dipeptides. J. Enzyme Inhib. 1997;11:151–169. doi: 10.3109/14756369709027647.
    1. Narra K., Mullins S.R., Lee H.O., Strzemkowski-Brun B., Magalong K., Christiansen V.J., McKee P.A., Egleston B., Cohen S.J., Weiner L.M., et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol. Ther. 2007;6:1691–1699. doi: 10.4161/cbt.6.11.4874.
    1. Jansen K., De Winter H., Heirbaut L., Cheng J.D., Joossens J., Lambeir A.M., De Meester I., Augustyns K., Van Der Veken P. Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold. Medchemcomm. 2014;5:1700–1707. doi: 10.1039/C4MD00167B.
    1. Ryabtsova O., Jansen K., Van Goethem S., Joossens J., Cheng J.D., Lambeir A.M., De Meester I., Augustyns K., Van Der Veken P. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. Bioorganic Med. Chem. Lett. 2012;22:3412–3417. doi: 10.1016/j.bmcl.2012.03.107.
    1. Jansen K., Heirbaut L., Verkerk R., Cheng J.D., Joossens J., Cos P., Maes L., Lambeir A.M., De Meester I., Augustyns K., et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP) J. Med. Chem. 2014;57:3053–3074. doi: 10.1021/jm500031w.
    1. Šimková A., Bušek P., Šedo A., Konvalinka J. Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications. Biochim. Biophys. Acta Proteins Proteom. 2020;1868:140409. doi: 10.1016/j.bbapap.2020.140409.
    1. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., Gopinathan A., Tuveson D.A., Fearon D.T. Suppression of Antitumor. Science. 2010;330:827–830. doi: 10.1126/science.1195300.
    1. Hirata E., Girotti M.R., Viros A., Hooper S., Spencer-Dene B., Matsuda M., Larkin J., Marais R., Sahai E. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK Signaling. Cancer Cell. 2015;27:574–588. doi: 10.1016/j.ccell.2015.03.008.
    1. Su S., Chen J., Yao H., Liu J., Yu S., Lao L., Wang M., Luo M., Xing Y., Chen F., et al. CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell. 2018;172:841–856.e16. doi: 10.1016/j.cell.2018.01.009.
    1. Fiori M.E., Di Franco S., Villanova L., Bianca P., Stassi G., De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol. Cancer. 2019;18:1–16. doi: 10.1186/s12943-019-0994-2.
    1. Mishra R., Haldar S., Placencio V., Madhav A., Rohena-Rivera K., Agarwal P., Duong F., Angara B., Tripathi M., Liu Z., et al. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J. Clin. Investig. 2018;128:4472–4484. doi: 10.1172/JCI99397.
    1. Jesnowski R., Fürst D., Ringel J., Chen Y., Schrödel A., Kleeff J., Kolb A., Schareck W.D., Löhr M. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: Deactivation is induced by matrigel and N-acetylcysteine. Lab. Investig. 2005;85:1276–1291. doi: 10.1038/labinvest.3700329.
    1. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., Feig C., Nakagawa T., Caldwell M.E., Zecchini H.I., et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62:112–120. doi: 10.1136/gutjnl-2012-302529.
    1. Melissari M.T., Chalkidi N., Sarris M.E., Koliaraki V. Fibroblast Reprogramming in Gastrointestinal Cancer. Front. Cell Dev. Biol. 2020;8:1–9. doi: 10.3389/fcell.2020.00630.
    1. Sherman M.H., Yu R.T., Engle D.D., Ding N., Atkins A.R., Collisson E.A., Connor F., Van Dyke T., Kozlov S., Tseng T.W., et al. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. Cell. 2015;159:80–93. doi: 10.1016/j.cell.2014.08.007.
    1. Gorchs L., Ahmed S., Mayer C., Knauf A., Fernández Moro C., Svensson M., Heuchel R., Rangelova E., Bergman P., Kaipe H. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci. Rep. 2020;10:17444. doi: 10.1038/s41598-020-74368-3.
    1. Calais J. FAP: The next billion dollar nuclear theranostics target? J. Nucl. Med. 2020;61:163–165. doi: 10.2967/jnumed.119.241232.
    1. Fischer E., Chaitanya K., Wuëst T., Wadle A., Scott A.M., Van Den Broek M., Schibli R., Bauer S., Renner C. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin. Cancer Res. 2012;18:6208–6218. doi: 10.1158/1078-0432.CCR-12-0644.
    1. Giesel F.L., Kratochwil C., Lindner T., Marschalek M.M., Loktev A., Lehnert W., Debus J., Jäger D., Flechsig P., Altmann A., et al. 68 Ga-FAPI PET/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J. Nucl. Med. 2019;60:386–392. doi: 10.2967/jnumed.118.215913.
    1. Koerber S.A., Staudinger F., Kratochwil C., Adeberg S., Haefner M.F., Ungerechts G., Rathke H., Winter E., Lindner T., Syed M., et al. The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. J. Nucl. Med. 2020;61:1331–1336. doi: 10.2967/jnumed.119.237016.
    1. Syed M., Flechsig P., Liermann J., Windisch P., Staudinger F., Akbaba S., Koerber S.A., Freudlsperger C., Plinkert P.K., Debus J., et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur. J. Nucl. Med. Mol. Imaging. 2020;47:2836–2845. doi: 10.1007/s00259-020-04859-y.
    1. Watabe T., Liu Y., Kaneda-Nakashima K., Shirakami Y., Lindner T., Ooe K., Toyoshima A., Nagata K., Shimosegawa E., Haberkorn U., et al. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. J. Nucl. Med. 2020;61:563–569. doi: 10.2967/jnumed.119.233122.
    1. Toms J., Kogler J., Maschauer S., Daniel C., Schmidkonz C., Kuwert T., Prante O. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18 F-labeled FAP Inhibitor. J. Nucl. Med. 2020 doi: 10.2967/jnumed.120.242958.
    1. Kratochwil C., Flechsig P., Lindner T., Abderrahim L., Altmann A., Mier W., Adeberg S., Rathke H., Röhrich M., Winter H., et al. 68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. J. Nucl. Med. 2019;60:801–805. doi: 10.2967/jnumed.119.227967.
    1. Lindner T., Altmann A., Krämer S., Kleist C., Loktev A., Kratochwil C., Giesel F., Mier W., Marme F., Debus J., et al. Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy. J. Nucl. Med. 2020;61:1507–1513. doi: 10.2967/jnumed.119.239731.
    1. Lindner T., Loktev A., Altmann A., Giesel F., Kratochwil C., Debus J., Jäger D., Mier W., Haberkorn U. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J. Nucl. Med. 2018;59:1415–1422. doi: 10.2967/jnumed.118.210443.
    1. Loktev A., Lindner T., Burger E.M., Altmann A., Giesel F., Kratochwil C., Debus J., Marmé F., Jäger D., Mier W., et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J. Nucl. Med. 2019;60:1421–1429. doi: 10.2967/jnumed.118.224469.
    1. Loktev A., Lindner T., Mier W., Debus J., Altmann A., Jäger D., Giesel F., Kratochwil C., Barthe P., Roumestand C., et al. A tumor-imaging method targeting cancer-associated fibroblasts. J. Nucl. Med. 2018;59:1423–1429. doi: 10.2967/jnumed.118.210435.
    1. Meyer C., Dahlbom M., Lindner T., Vauclin S., Mona C., Slavik R., Czernin J., Haberkorn U., Calais J. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients. J. Nucl. Med. 2020;61:1171–1177. doi: 10.2967/jnumed.119.236786.
    1. Röhrich M., Loktev A., Wefers A.K., Altmann A., Paech D., Adeberg S., Windisch P., Hielscher T., Flechsig P., Floca R., et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2019;46:2569–2580. doi: 10.1007/s00259-019-04444-y.
    1. Shi X., Xing H., Yang X., Li F., Yao S., Zhang H., Zhao H., Hacker M., Huo L., Li X. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: A pilot study in patients with suspected hepatic nodules. Eur. J. Nucl. Med. Mol. Imaging. 2020 doi: 10.1007/s00259-020-04882-z.
    1. Poeppel T.D., Binse I., Petersenn S., Lahner H., Schott M., Antoch G., Brandau W., Bockisch A., Boy C. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J. Nucl. Med. 2011;52:1864–1870. doi: 10.2967/jnumed.111.091165.
    1. Kurash M.M., Gill R., Khairulin M., Harbosh H., Keidar Z. 68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: Normal biodistribution and uptake characteristics of tumour lesions. Sci. Rep. 2020;10:3109. doi: 10.1038/s41598-020-60099-y.
    1. Giesel F., Adeberg S., Syed M., Lindner T., Jimenez L.D., Mavriopoulou E., Staudinger F., Tonndorf-Martini E., Regnery S., Rieken S., et al. FAPI-74 PET/CT Using Either 18 F-AlF or Cold-kit 68 Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients. J. Nucl. Med. 2020 doi: 10.2967/jnumed.120.245084.
    1. Chen H., Pang Y., Wu J., Zhao L., Hao B., Wu J., Wei J., Wu S., Zhao L., Luo Z., et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur. J. Nucl. Med. Mol. Imaging. 2020;47:1820–1832. doi: 10.1007/s00259-020-04769-z.
    1. Imaging of Solid Tumors Using 68Ga-FAP-2286—Full Text View— [Internet] [(accessed on 18 February 2021)]; Available online: .
    1. Hirmas N., Jadaan R., Al-Ibraheem A. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives. Nucl. Med. Mol. Imaging. 2018;52:190–199. doi: 10.1007/s13139-018-0517-x.
    1. Wang Y., Weng J., Wen X., Hu Y., Ye D. Recent advances in stimuli-responsive in situ self-assembly of small molecule probes for in vivo imaging of enzymatic activity. Biomater. Sci. 2021 doi: 10.1039/D0BM00895H.
    1. De Decker A., Vliegen G., Van Rompaey D., Peeraer A., Bracke A., Verckist L., Jansen K., Geiss-Friedlander R., Augustyns K., De Winter H., et al. Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP) ACS Med. Chem. Lett. 2019;10:1173–1179. doi: 10.1021/acsmedchemlett.9b00191.
    1. Wang Q., Guan J., Wan J., Li Z. Disulfide based prodrugs for cancer therapy. RSC Adv. 2020;10:24397–24409. doi: 10.1039/D0RA04155F.
    1. Giang I., Boland E.L., Poon G.M.K. Prodrug applications for targeted cancer therapy. AAPS J. 2014;16:899–913. doi: 10.1208/s12248-014-9638-z.
    1. Kim E.J., Bhuniya S., Lee H., Kim H.M., Cheong C., Maiti S., Hong K.S., Kim J.S. An activatable prodrug for the treatment of metastatic tumors. J. Am. Chem. Soc. 2014;136:13888–13894. doi: 10.1021/ja5077684.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel